GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputGlobeNewsWire • 09/14/26
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsGlobeNewsWire • 09/04/26
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity PharmaceuticalsGlobeNewsWire • 07/13/26
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceGlobeNewsWire • 06/26/26
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsGlobeNewsWire • 04/03/26
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsGlobeNewsWire • 02/13/25
Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee ChairGlobeNewsWire • 02/07/25
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionGlobeNewsWire • 10/31/24
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/14/24
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024GlobeNewsWire • 08/07/24
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramGlobeNewsWire • 06/24/24
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.GlobeNewsWire • 06/13/24
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024GlobeNewsWire • 05/16/24
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/09/24
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024GlobeNewsWire • 05/02/24
Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/27/24
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationGlobeNewsWire • 03/25/24